E-LIB Suche - Ergebnisse für: Fajac, I.

1

ECFS standards of care on CFTR-related disorders: Towards a..:

De Wachter, E ; De Boeck, K ; Sermet-Gaudelus, I...
Journal of Cystic Fibrosis. 23 (2024) 3 - p. 388-397 , 2024

Link: https://doi.org/10.1016/..

2

P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety..:

Davies, J.C. ; Mall, M.A. ; Polineni, D....
Journal of Cystic Fibrosis. 23 (2024) - p. S80 , 2024

Link: https://doi.org/10.1016/..

3

P046 Lenticlair™-ON: An extension trial examining long-term..:

Davies, J.C. ; Mall, M.A. ; Polineni, D....
Journal of Cystic Fibrosis. 23 (2024) - p. S80 , 2024

Link: https://doi.org/10.1016/..

4

WS11.04 Evaluation of lung computed tomography screening of..:

Di Mango, E. ; Engel, A.T. ; Fajac, I....
Journal of Cystic Fibrosis. 23 (2024) - p. S21 , 2024

Link: https://doi.org/10.1016/..

5

P481 MRI as a follow-up to lung CT to evaluate suspicious l..:

Wucherpfennig, L. ; Wielpütz, M.O. ; Salvatore, M....
Journal of Cystic Fibrosis. 23 (2024) - p. S116 , 2024

Link: https://doi.org/10.1016/..

6

WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivaca..:

Castellani, C. ; Mondejar-Lopez, P. ; Quon, B.S....
Journal of Cystic Fibrosis. 23 (2024) - p. S11 , 2024

Link: https://doi.org/10.1016/..

7

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aqu..:

Girodon, E. ; Lopez, M. ; Sperelakis-Beedham, B....
Journal of Cystic Fibrosis. 21 (2022) - p. S41 , 2022

Link: https://doi.org/10.1016/..

8

185 Long-term safety and efficacy of elexacaftor/tezacaftor..:

Chmiel, J. ; Barry, P.J. ; Colombo, C....
Journal of Cystic Fibrosis. 21 (2022) - p. S108-S109 , 2022

Link: https://doi.org/10.1016/..

9

Genomically-guided therapies: A new era for cystic fibrosis:

Fajac, I. ; Girodon, E.
Archives de Pédiatrie. 27 (2020) - p. eS41-eS44 , 2020

Link: https://doi.org/10.1016/..

10

WS11.5 Evaluation of combinations of the CFTR potentiator d..:

Downey, D. G ; Fajac, I. ; Flume, P....
Journal of Cystic Fibrosis. 19 (2020) - p. S19 , 2020

Link: https://doi.org/10.1016/..

11

ePS3.10 Patient demographics and baseline disease character..:

Chiron, R. ; Elborn, J.S. ; Flume, P....
Journal of Cystic Fibrosis. 19 (2020) - p. S45-S46 , 2020

Link: https://doi.org/10.1016/..

12

Cystic fibrosis drug trial design in the era of CFTR modula..:

De Boeck, K. ; Lee, T. ; Amaral, M....
Journal of Cystic Fibrosis. 19 (2020) 5 - p. 688-695 , 2020

Link: https://doi.org/10.1016/..

13

Building global development strategies for cf therapeutics ..:

Mayer-Hamblett, N. ; van Koningsbruggen-Rietschel, S. ; Nichols, D.P....
Journal of Cystic Fibrosis. 19 (2020) 5 - p. 677-687 , 2020

Link: https://doi.org/10.1016/..

14

P222 An update on BALANCE-CF™ 1: a Phase II trial of the in..:

Fajac, I. ; Mall, M.A. ; Jain, R....
Journal of Cystic Fibrosis. 19 (2020) - p. S119 , 2020

Link: https://doi.org/10.1016/..

15

WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/..:

Majoor, C. ; Van Brunt, K. ; Daines, C....
Journal of Cystic Fibrosis. 19 (2020) - p. S32 , 2020

Link: https://doi.org/10.1016/..